Evolution of the Synthesis of Remdesivir. Classical Approaches and Most Recent Advances
Didier F. Vargas, Enrique L. Larghi, Teodoro S. Kaufman
Abstract
The broad-spectrum antiviral Remdesivir, a monophosphate nucleoside analogue prodrug (ProTide), was repurposed. In May 2020, it received emergency approval by the FDA, being the first drug approved to fight the new coronavirus (COVID-19) disease which targets the virus directly. The main synthetic strategies toward Remdesivir, and their relevant modifications, are presented and discussed, to provide a panoramic view of the state-of-the-art and the more important advances in this field. Recent progress, proposed improvements, and uses of novel technologies for the synthetic sequence are also detailed.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Prodrug2019-20 coronavirus outbreakCoronavirusVirologyComputational biologyComputer scienceMedicineNanotechnologyPharmacologyDiseaseBiologyInfectious disease (medical specialty)Materials sciencePathologyOutbreakSynthesis and biological activityQuinazolinone synthesis and applicationsTuberculosis Research and Epidemiology